Loading
companiesCompany
Convergent Therapeutics
Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results.
Overview
Convergent Therapeutics develops alpha radioantibodies: antibodies that deliver alpha-emitting payloads directly into cancer cells while limiting exposure of healthy tissue. The lead candidate CONV01-α is a PSMA-directed actinium-225 radioantibody for metastatic castration-resistant prostate cancer in patients previously treated with 177Lu-PSMA. In June 2026 the company presented what it described as the largest prospective phase 2 dataset for an alpha radiopharmaceutical at ASCO 2026, reporting anti-tumour activity, durability and favourable tolerability in Lu-PSMA-exposed mCRPC.
Notes
top- The Business Wire releases (ASCO 2026 data, Series A) returned HTTP 403, so funding is omitted; trade press headlines report a USD 90 million Series A (2023) and a USD 40 million extension, unverified here. The domains convergenttx.com and convergenttherapeutics.com are parked; convergentrx.com blocks scripted requests but was fetched via WebFetch.
Similar pages
- CompanyARTBIO
Shares Targeted alpha therapy, PSMA, Prostate cancer.
- TechnologyAuger-electron therapy
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, PSMA.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer.
- CompanyActinium Pharmaceuticals
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Prostate cancer.
- PersonClemens Kratochwil
Shares Targeted alpha therapy, PSMA, Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer.
- TrialPSMA-PET to Guide Prostatectomy
Shares PSMA, Prostate cancer.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares PSMA, Prostate cancer.